MK0524A Phase IIb Study (0524A-011)(COMPLETED)
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Part A: This study will determine that MK0524 is well tolerated and does not effect lipids
 and blood glucose when given alone.

 Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids
 and blood glucose.
Inclusion Criteria:

 -  Men and women, 18 to 70 years of age for whom treatment with Niacin would be
 appropriate but who are not taking > 50mg at screening

 -  Must be willing to complete electronic diary

 Exclusion Criteria:

 -  Subject is having menopausal hot flashes and/or receiving hormone replacement therapy
 (HRT)

 -  You have a history of cancer, gout, peptic ulcers, diabetes, liver, heart disease or
 high blood pressure or you are HIV positive

 -  You consume more than 14 alcoholic drinks per week or more than 2 drinks per day